NTLAHealthcare · BiotechnologyThe 19 Wall Street analysts covering Intellia Therapeutics, Inc. hold a median 12-month price target of $17 — +44.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 12 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Intellia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (94): Sales and profits are climbing, and climbing faster than before.
Volatility (21): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NTLA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +44.8% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | Citizens | Reiterates | Market Outperform | $30 |
| 9 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 9 Sept 2026 | Wedbush | Maintains | Neutral | $12 → $13 |
| 25 Aug 2026 | Citizens | Reiterates | Market Outperform | $30 |
| 7 Aug 2026 | Evercore ISI Group | Upgrade | Outperform | $16 → $24 |
| 7 Aug 2026 | Evercore ISI Group | Upgrade | Outperform | — |
| 16 July 2026 | Wolfe Research | Downgrade | Underperform | $9.00 |
| 16 July 2026 | Wolfe Research | Downgrade | Underperform | — |
| 10 July 2026 | Wedbush | Maintains | Neutral | $12 → $17 |
| 10 July 2026 | Wedbush | Maintains | Neutral | — |
| 16 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 15 June 2026 | Citizens | Reiterates | Market Outperform | — |
| 15 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 June 2026 | Wedbush | Reiterates | Neutral | — |
| 13 May 2026 | Bernstein | Maintains | Market Perform | — |
| 13 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 12 May 2026 | Wedbush | Reiterates | Neutral | — |
| 28 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 28 Apr 2026 | Citizens | Maintains | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NTLA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Intellia Therapeutics, Inc. returned +2.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 8% of US stocks
Cheaper than 42% of US stocks
Cheaper than 75% of US stocks
Higher than 6% of US stocks
Higher than 11% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
Higher than 20% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Intellia Therapeutics, Inc. has a market value of $1.6B and an enterprise value of $1.3B.
Revenue in the twelve months to 30 June 2026: $59.5M. The latest quarter shrank 46.2% year on year.
Net income over the same four quarters: −$400.0M, a −672.2% net margin.
Diluted earnings per share, trailing twelve months: $−3.36.
Free cash flow in the twelve months to 30 June 2026: −$348.7M.
Trailing P/E: −3.1×; forward P/E: −4.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Intellia Therapeutics, Inc. employs 377 people — $158K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Intellia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The FDA has accepted Intellia's Biologics License Application (BLA) for its hereditary angioedema (HAE) drug, lonvo-z, and granted it Priority Review. A regulatory decision is expected by March 10, 2027.
Why it matters — Priority Review signals faster regulatory evaluation of Intellia's HAE candidate, bringing the company closer to a potential approval decision.
Zacks Investment Research highlights Intellia Therapeutics (NTLA) alongside WGS and NEO as a promising genomics stock in 2026, noting that genomics is reshaping healthcare through advances in diagnostics and precision medicine.
Why it matters — The mention positions NTLA among notable genomics companies advancing precision medicine, which is relevant context for investors tracking the sector.
Intellia Therapeutics announced the FDA has accepted its Biologics License Application for lonvoguran ziclumeran (lonvo-z), a CRISPR-based therapy for hereditary angioedema, and granted it Priority Review with a PDUFA target action date of March 10, 2027. If approved, lonvo-z would be the world's first in vivo CRISPR-based therapy and the only one-time HAE treatment.
Why it matters — An NTLA watcher would care because FDA acceptance with Priority Review advances Intellia's lead candidate toward potential approval and a near-term regulatory decision date.
Intellia Therapeutics announced that on September 1, 2026, it awarded inducement grants under its 2024 Inducement Plan to 41 new employees as a material inducement to their employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters — NTLA watchers would care because the inducement grants signal continued hiring and workforce expansion at the gene-editing biopharmaceutical company.
Intellia Therapeutics announced a non-dilutive debt facility with OrbiMed of up to $400 million. The agreement includes $75 million funded upfront, with an additional $325 million tied to achieving milestones.
Why it matters — The non-dilutive financing provides Intellia with strategic flexibility through anticipated value inflection points without issuing additional equity.
The 19 Wall Street analysts covering Intellia Therapeutics, Inc. have a median 12-month price target of $17, with estimates ranging from $8 to $61. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 19 analysts covering Intellia Therapeutics, Inc., 10 rate it a Buy, 6 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Intellia Therapeutics, Inc. 51 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Intellia Therapeutics, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).
No one can know that. What the data says: the median 12-month target from 19 analysts implies +44.8% from the last close, and Ticker Nerd's factor model ranks Intellia Therapeutics, Inc. 51 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Intellia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $61 over the next 12 months.
Intellia Therapeutics, Inc. returned +2.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing medicines built on CRISPR/Cas9 technology.
The most recent item we track (Zacks Investment Research, 9 Sept 2026): "FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug". The FDA has accepted Intellia's Biologics License Application (BLA) for its hereditary angioedema (HAE) drug, lonvo-z, and granted it Priority Review. A regulatory decision is expected by March 10, 2027.
Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing medicines built on CRISPR/Cas9 technology. Intellia Therapeutics develops both in vivo therapies, which edit genes inside the body, and ex vivo cell therapies, where cells are edited outside the body before being returned to the patient. Its current programs are centered on severe genetic and immune-related diseases, including rare disorders such as transthyretin amyloidosis and hereditary angioedema, as well as selected oncology and autoimmune applications. The company’s broader role in the market is to advance potentially curative treatment approaches that address the root cause of disease rather than symptoms. Intellia Therapeutics operates as a research-driven biopharmaceutical company, with a business model centered on clinical development, collaboration, and platform-based innovation in genetic medicine.
CEO Dr. John M. Leonard M.D. · 377 employees · United States · https://www.intelliatx.com
